Navigation Links
OrthoAccel Technologies, Inc. Announces New Chief Financial Officer
Date:12/7/2011

HOUSTON, Dec. 7, 2011 /PRNewswire/ -- OrthoAccel Technologies, Inc., developers of the AcceleDent™ System, which is an acceleration device to enhance orthodontics, announced a new CFO, Andrew Layman, this week.  Mr. Layman began effective December 1, and will oversee all administrative and finance functions at OrthoAccel.

AcceleDent is a simple, removable and non-invasive appliance that a patient wears with braces or aligners in the mouth for 20 minutes daily to accelerate orthodontic tooth movement. The Company announced FDA clearance last month.  A randomized, controlled clinical trial conducted at the University of Texas Health Science Center at San Antonio demonstrated, with statistical significance, that tooth movement could be accelerated by 106% during the alignment phase and 38% to 50% during space closure.  There was no evidence of incremental root resorption or adverse events, thus demonstrating an excellent safety profile for the appliance.

Mr. Layman joins OrthoAccel as it prepares for its US market launch, amidst growing sales outside of the US.  He brings a diverse background that spans international finance, accounting, audit, and tax experience.  Mr. Layman is a CPA, and previously spent eight years at a "Big Four" public accounting firm.  His operating experience is broad, ranging from start-up to financial responsibility for a $3 billion division at Flextronics International, a leading electronics manufacturing services provider to the world's top technology brands.

Michael Lowe, CEO of OrthoAccel, commented, "We knew that 2012 would involve managing significant growth, and that it would be important to bring in an experienced finance executive."    Product availability to US doctors is scheduled for January 2012.  "We could not be more pleased with where the process led us.  Andy is a perfect fit in every way.  His track record for establishing risk management and internal controls will be an important part of our growth," Lowe continued. 

Mr. Layman remarked, "I am very pleased to join the management team at OrthoAccel during this exciting, rapid growth time."

Last month, in addition to FDA clearance, the Company announced a major partnership with a distributor in the Italy market.  Plans related to additional clinical trial activity with key university partners, both inside and outside of the US, are scheduled to be announced in the first quarter of 2012.

About OrthoAccel® Technologies, Inc.
Based in Houston, Texas, OrthoAccel® Technologies, Inc. is a privately owned medical device company currently engaged in the development, manufacturing, and marketing of products to enhance dental care and orthodontic treatment. OrthoAccel currently sells its products in ten markets world-wide and received FDA clearance in November 2011 for the AcceleDent™ System. Product availability for US doctors is scheduled for January 2012.

About the AcceleDent™ System
AcceleDent™
represents the first clinical approach to accelerate orthodontic tooth movement via modulating bone biology. The appliance has been studied clinically as a complement to conventional fixed orthodontic appliances to apply gentle pulsing forces to the dentition to move teeth faster through accelerated bone remodeling. More information can be found at www.acceledent.com and www.acceledent.co.uk or requested via info@orthoaccel.com.


'/>"/>
SOURCE OrthoAccel Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OrthoAccel Technologies, Inc. and AB Orthodontics Announce Partnership and Australian Product Introduction
2. OrthoAccel Technologies, Inc. Announces Definitive Distribution Agreements in Two Key Markets
3. OrthoAccel Technologies Announces Full-Market Release of AcceleDent, a New Technology to Shorten Treatment Time in Braces
4. OrthoAccel Technologies Committed to Plans for Positioning the United Kingdom as a Key Strategic Market for New Orthodontic Technology
5. Medical Device Industry Executive Joins OrthoAccel Technologies, Inc. Board of Directors
6. OrthoAccel Technologies, Inc. Announces New Scientific Advisor
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
10. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
11. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... January 19, 2017 Incretin Mimetics/GLP-1 Agonists, SNDRIs, ... The global anti-obesity drugs market is expected ... of the forecast period and CAGR of 38.7% in the second ... at a CAGR of 32.8% from 2016 to 2027. The market ... and $24,063 million in 2027. ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017 Accuray ... its CyberKnife® and TomoTherapy® Systems continue to set the ... received the highest composite overall user satisfaction rating among ... the Q4 2016 MD Buyline Market Intelligence Briefing™. The ... the highest composite ratings among industry peers for 11 ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... Grothey ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... http://photos.prnewswire.com/prnh/20151014/276718LOGO) Published recently in ... the peer-reviewed journal from touchONCOLOGY, an article by ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Allegheny Health Network (AHN) officials today announced a ... the Network’s programs and services in the greater Pittsburgh region. Starting January 23, patients ... offered one for that same afternoon. , AHN is the first ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... asset protection and financial planning services to communities throughout eastern Georgia, is embarking ... against heart disease. , Heart disease kills more Americans every year than anything ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... owned insurance agency which serves Lawrenceville, New Jersey and the surrounding area, ... , Amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease or ...
(Date:1/19/2017)... ... ... Attorney Robert “RC” Pate , founder of The Law Office of ... Kid Cancer foundation. Each year, 175,000 children are diagnosed with pediatric cancers. In 2006, ... of the critical funding gap for research into pediatric cancer research. From 2006 onwards, ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the second ... Associates of Connecticut (RMACT) have earned “Top Doctor” awards. Dr. Mark Leondires, Dr. ... have each been chosen by their peers for the 2017 list based on ...
Breaking Medicine News(10 mins):